Cargando…

Understanding Protein–Nanoparticle Interaction: A New Gateway to Disease Therapeutics

[Image: see text] Molecular identification of protein molecules surrounding nanoparticles (NPs) may provide useful information that influences NP clearance, biodistribution, and toxicity. Hence, nanoproteomics provides specific information about the environment that NPs interact with and can therefo...

Descripción completa

Detalles Bibliográficos
Autores principales: Giri, Karuna, Shameer, Khader, Zimmermann, Michael T., Saha, Sounik, Chakraborty, Prabir K., Sharma, Anirudh, Arvizo, Rochelle R., Madden, Benjamin J., Mccormick, Daniel J., Kocher, Jean-Pierre A., Bhattacharya, Resham, Mukherjee, Priyabrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128259/
https://www.ncbi.nlm.nih.gov/pubmed/24831101
http://dx.doi.org/10.1021/bc500084f
_version_ 1782330108267200512
author Giri, Karuna
Shameer, Khader
Zimmermann, Michael T.
Saha, Sounik
Chakraborty, Prabir K.
Sharma, Anirudh
Arvizo, Rochelle R.
Madden, Benjamin J.
Mccormick, Daniel J.
Kocher, Jean-Pierre A.
Bhattacharya, Resham
Mukherjee, Priyabrata
author_facet Giri, Karuna
Shameer, Khader
Zimmermann, Michael T.
Saha, Sounik
Chakraborty, Prabir K.
Sharma, Anirudh
Arvizo, Rochelle R.
Madden, Benjamin J.
Mccormick, Daniel J.
Kocher, Jean-Pierre A.
Bhattacharya, Resham
Mukherjee, Priyabrata
author_sort Giri, Karuna
collection PubMed
description [Image: see text] Molecular identification of protein molecules surrounding nanoparticles (NPs) may provide useful information that influences NP clearance, biodistribution, and toxicity. Hence, nanoproteomics provides specific information about the environment that NPs interact with and can therefore report on the changes in protein distribution that occurs during tumorigenesis. Therefore, we hypothesized that characterization and identification of protein molecules that interact with 20 nm AuNPs from cancer and noncancer cells may provide mechanistic insights into the biology of tumor growth and metastasis and identify new therapeutic targets in ovarian cancer. Hence, in the present study, we systematically examined the interaction of the protein molecules with 20 nm AuNPs from cancer and noncancerous cell lysates. Time-resolved proteomic profiles of NP-protein complexes demonstrated electrostatic interaction to be the governing factor in the initial time-points which are dominated by further stabilization interaction at longer time-points as determined by ultraviolet–visible spectroscopy (UV–vis), dynamic light scattering (DLS), ζ-potential measurements, transmission electron microscopy (TEM), and tandem mass spectrometry (MS/MS). Reduction in size, charge, and number of bound proteins were observed as the protein-NP complex stabilized over time. Interestingly, proteins related to mRNA processing were overwhelmingly represented on the NP-protein complex at all times. More importantly, comparative proteomic analyses revealed enrichment of a number of cancer-specific proteins on the AuNP surface. Network analyses of these proteins highlighted important hub nodes that could potentially be targeted for maximal therapeutic advantage in the treatment of ovarian cancer. The importance of this methodology and the biological significance of the network proteins were validated by a functional study of three hubs that exhibited variable connectivity, namely, PPA1, SMNDC1, and PI15. Western blot analysis revealed overexpression of these proteins in ovarian cancer cells when compared to normal cells. Silencing of PPA1, SMNDC1, and PI15 by the siRNA approach significantly inhibited proliferation of ovarian cancer cells and the effect correlated with the connectivity pattern obtained from our network analyses.
format Online
Article
Text
id pubmed-4128259
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-41282592015-05-15 Understanding Protein–Nanoparticle Interaction: A New Gateway to Disease Therapeutics Giri, Karuna Shameer, Khader Zimmermann, Michael T. Saha, Sounik Chakraborty, Prabir K. Sharma, Anirudh Arvizo, Rochelle R. Madden, Benjamin J. Mccormick, Daniel J. Kocher, Jean-Pierre A. Bhattacharya, Resham Mukherjee, Priyabrata Bioconjug Chem [Image: see text] Molecular identification of protein molecules surrounding nanoparticles (NPs) may provide useful information that influences NP clearance, biodistribution, and toxicity. Hence, nanoproteomics provides specific information about the environment that NPs interact with and can therefore report on the changes in protein distribution that occurs during tumorigenesis. Therefore, we hypothesized that characterization and identification of protein molecules that interact with 20 nm AuNPs from cancer and noncancer cells may provide mechanistic insights into the biology of tumor growth and metastasis and identify new therapeutic targets in ovarian cancer. Hence, in the present study, we systematically examined the interaction of the protein molecules with 20 nm AuNPs from cancer and noncancerous cell lysates. Time-resolved proteomic profiles of NP-protein complexes demonstrated electrostatic interaction to be the governing factor in the initial time-points which are dominated by further stabilization interaction at longer time-points as determined by ultraviolet–visible spectroscopy (UV–vis), dynamic light scattering (DLS), ζ-potential measurements, transmission electron microscopy (TEM), and tandem mass spectrometry (MS/MS). Reduction in size, charge, and number of bound proteins were observed as the protein-NP complex stabilized over time. Interestingly, proteins related to mRNA processing were overwhelmingly represented on the NP-protein complex at all times. More importantly, comparative proteomic analyses revealed enrichment of a number of cancer-specific proteins on the AuNP surface. Network analyses of these proteins highlighted important hub nodes that could potentially be targeted for maximal therapeutic advantage in the treatment of ovarian cancer. The importance of this methodology and the biological significance of the network proteins were validated by a functional study of three hubs that exhibited variable connectivity, namely, PPA1, SMNDC1, and PI15. Western blot analysis revealed overexpression of these proteins in ovarian cancer cells when compared to normal cells. Silencing of PPA1, SMNDC1, and PI15 by the siRNA approach significantly inhibited proliferation of ovarian cancer cells and the effect correlated with the connectivity pattern obtained from our network analyses. American Chemical Society 2014-05-15 2014-06-18 /pmc/articles/PMC4128259/ /pubmed/24831101 http://dx.doi.org/10.1021/bc500084f Text en Copyright © 2014 American Chemical Society Terms of Use (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html)
spellingShingle Giri, Karuna
Shameer, Khader
Zimmermann, Michael T.
Saha, Sounik
Chakraborty, Prabir K.
Sharma, Anirudh
Arvizo, Rochelle R.
Madden, Benjamin J.
Mccormick, Daniel J.
Kocher, Jean-Pierre A.
Bhattacharya, Resham
Mukherjee, Priyabrata
Understanding Protein–Nanoparticle Interaction: A New Gateway to Disease Therapeutics
title Understanding Protein–Nanoparticle Interaction: A New Gateway to Disease Therapeutics
title_full Understanding Protein–Nanoparticle Interaction: A New Gateway to Disease Therapeutics
title_fullStr Understanding Protein–Nanoparticle Interaction: A New Gateway to Disease Therapeutics
title_full_unstemmed Understanding Protein–Nanoparticle Interaction: A New Gateway to Disease Therapeutics
title_short Understanding Protein–Nanoparticle Interaction: A New Gateway to Disease Therapeutics
title_sort understanding protein–nanoparticle interaction: a new gateway to disease therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128259/
https://www.ncbi.nlm.nih.gov/pubmed/24831101
http://dx.doi.org/10.1021/bc500084f
work_keys_str_mv AT girikaruna understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT shameerkhader understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT zimmermannmichaelt understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT sahasounik understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT chakrabortyprabirk understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT sharmaanirudh understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT arvizorocheller understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT maddenbenjaminj understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT mccormickdanielj understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT kocherjeanpierrea understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT bhattacharyaresham understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics
AT mukherjeepriyabrata understandingproteinnanoparticleinteractionanewgatewaytodiseasetherapeutics